BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and ...

Eyecare company Bausch + Lomb (NYSE:BLCO) reported in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the ...

Equities researchers at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Bausch + Lomb in a research report issued on Tuesday, February 18th. HC Wainwright analyst Y. Chen ...

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally.

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.

Shares of Bausch Health Companies Inc. BHC gained 2.36% after the company reported better-than-expected fourth-quarter ...

Reports Q4 revenue $1.28B, consensus $1.25B. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent ...

In a report released today, David Saxon from Needham maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report). The ...

Bausch + Lomb saw a broad-based growth across its three core segments. Vision care, its largest, saw revenue rise 9% to $723 million, while surgical increased 13% to $231 million. Pharmaceuticals rose ...

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

VAUGHAN, Ontario (AP) — VAUGHAN, Ontario (AP) — Bausch + Lomb Corporation (BLCO) on Wednesday reported a loss of $3 million in its fourth quarter. On a per-share basis, the Vaughan, Ontario-based ...